D Recalde

Summary

Affiliation: University of Zaragoza
Country: Spain

Publications

  1. ncbi Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-I(Zaragoza) (L144R)
    D Recalde
    Departamento de Bioquimica y Biologia Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009, Zaragoza, Spain
    Atherosclerosis 154:613-23. 2001
  2. ncbi Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia
    E Meriño Ibarra
    Lipid Unit and Molecular Research Laboratory, Hospital Universitario Miguel Servet, Instituto Aragones de Ciencias de la Salud, Avda Isabel La Catolica 1 3, 50009, Zaragoza, Spain
    J Inherit Metab Dis 30:970-7. 2007
  3. ncbi Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment
    A L Garcia-Otin
    Departamento de Bioquimica y Biologia Molecular y Celular, Universidad de Zaragoza, Spain
    Eur J Clin Invest 32:421-8. 2002

Collaborators

Detail Information

Publications3

  1. ncbi Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-I(Zaragoza) (L144R)
    D Recalde
    Departamento de Bioquimica y Biologia Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009, Zaragoza, Spain
    Atherosclerosis 154:613-23. 2001
    ....
  2. ncbi Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia
    E Meriño Ibarra
    Lipid Unit and Molecular Research Laboratory, Hospital Universitario Miguel Servet, Instituto Aragones de Ciencias de la Salud, Avda Isabel La Catolica 1 3, 50009, Zaragoza, Spain
    J Inherit Metab Dis 30:970-7. 2007
    ..Autosomal dominant hypercholesterolaemia (ADH) are a heterogeneous group of monogenic lipid disorders. The plasma level of lipoprotein(a) (Lp(a)) is a heritable trait associated with increased coronary heart disease (CHD) risk...
  3. ncbi Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment
    A L Garcia-Otin
    Departamento de Bioquimica y Biologia Molecular y Celular, Universidad de Zaragoza, Spain
    Eur J Clin Invest 32:421-8. 2002
    ..We have investigated whether common polymorphisms and mutations in the apolipoprotein (apo) E, lipoprotein lipase (LPL), and apo CIII genes influence atorvastatin or bezafibrate responses in patients with CHL...